For example, low-dose IL-2 therapy, which protects NOD mice from diabetes (131) and is currently being trialed in human T1D, expanded Treg in the gut mucosa and led to an altered gut microbiota in NOD mice (40). Here, IL2 is linked to type 1 diabetes mellitus.